Evaluation of Response to Two Schedules of Capecitabine in Patients With Metastatic Breast Cancer

Trial Profile

Evaluation of Response to Two Schedules of Capecitabine in Patients With Metastatic Breast Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Sep 2018

At a glance

  • Drugs Capecitabine (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Sep 2018 Planned End Date changed from 1 Mar 2018 to 1 Mar 2019.
    • 06 Sep 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Dec 2018.
    • 22 Dec 2017 Planned End Date changed from 1 Dec 2016 to 1 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top